Thoracic Imaging

Why Is Imaging Not Recommended for Low-Risk Lung Cancer Screening?

·
Why Is Imaging Not Recommended for Low-Risk Lung Cancer Screening?

A 48-year-old patient is in your office for a routine physical. They have a 15 pack-year smoking history but quit five years ago. They have no other significant medical history or risk factors for lung cancer. Prompted by a public health campaign, they ask, “Should I get a CT scan to check for lung cancer?” You now face the decision of whether to order screening imaging for a patient who falls outside the established high-risk criteria. This article addresses the specific American College of Radiology (ACR) Appropriateness Criteria for this low-risk screening scenario. For this patient, the ACR guidance is clear: screening with any imaging modality, including low-dose computed tomography (CT) or chest radiography, is rated as Usually not appropriate.

Who Fits This Clinical Scenario?

This guidance applies to a specific group of asymptomatic individuals being considered for lung cancer screening. The key inclusion criteria are a smoking history of less than 20 pack-years and the absence of any additional major risk factors. This includes patients of any age who do not meet the high-risk threshold established by major clinical trials and adopted by the United States Preventive Services Task Force (USPSTF).

It is critical to distinguish this patient from those in higher-risk categories for whom screening is recommended. This workflow does not apply to:

  • High-Risk Patients: Individuals aged 50 to 80 years with a 20 pack-year or greater smoking history who currently smoke or have quit within the past 15 years. For this group, annual low-dose CT screening is considered Usually appropriate.
  • Intermediate-Risk Patients: Individuals who may not meet the strict age and smoking criteria but have other significant risk factors, such as a personal history of cancer, a first-degree relative with lung cancer, or a history of chronic obstructive pulmonary disease (COPD) or pulmonary fibrosis. These scenarios are evaluated under different ACR variants.

This article is exclusively for the low-risk patient, where the central clinical question is not which study to order, but whether to order a study at all.

What Are the Clinical Considerations in This Scenario?

In a low-risk patient, the decision against screening is not a dismissal of concern but a careful balancing of potential benefits against tangible harms. The “workup” involves weighing the low probability of finding a life-threatening cancer against the high probability of encountering issues caused by the screening process itself.

Low Pre-Test Probability of Lung Cancer: The fundamental issue is that the prevalence of lung cancer in this population is very low. Major screening trials, like the National Lung Screening Trial (NLST), focused on high-risk individuals because that is where the benefit of early detection was most likely to be found. In a low-risk group, the vast majority of screening tests will be negative, and the number of individuals you would need to screen to prevent one lung cancer death becomes prohibitively high.

High Rate of Benign Incidental Findings: Chest imaging is notoriously sensitive for small nodules, the vast majority of which are benign (e.g., granulomas, intrapulmonary lymph nodes). In the NLST, nearly a quarter of high-risk participants had a positive screen, but over 96% of these positive findings were false positives. In a low-risk population, the false-positive rate would be even higher, triggering a cascade of unnecessary follow-up scans and anxiety.

Risks from Downstream Procedures: A “positive” screening scan often leads to further investigation, which can include serial CT scans, PET/CT, and potentially invasive procedures like bronchoscopy or needle biopsy to evaluate a benign nodule. These procedures carry their own risks, including pneumothorax, bleeding, and infection, which are not justified when the initial likelihood of malignancy is extremely low.

Radiation Exposure and Overdiagnosis: While a single low-dose CT carries a small radiation dose, the commitment to annual screening implies cumulative exposure over many years. Furthermore, screening can lead to overdiagnosis—the detection of indolent cancers that would never have become clinically significant or caused harm, leading to unnecessary treatment and its associated morbidity.

Why Is Screening Imaging Not Recommended for This Patient?

Based on the principle of balancing benefits and harms, the ACR rates all imaging modalities as Usually not appropriate for lung cancer screening in this low-risk population. The evidence from large-scale trials does not support a net benefit for these individuals.

The primary modality for high-risk screening, CT chest without IV contrast screening (low-dose CT), is rated Usually not appropriate here. The rationale is directly tied to the low pre-test probability of disease. The harms—including high false-positive rates, patient anxiety, costs, radiation exposure (adult RRL=☢☢☢ 1-10 mSv), and complications from the workup of benign nodules—are expected to outweigh the potential benefit of detecting a rare cancer in this group. There is no high-quality evidence to suggest that screening this population reduces lung cancer mortality.

Other imaging modalities are even less suitable and are also rated Usually not appropriate:

  • Radiography chest: While having a very low radiation dose (adult RRL=☢ <0.1 mSv), chest X-ray lacks the sensitivity to detect the small, early-stage nodules that are the target of screening. Its use for screening was studied and found to be ineffective at reducing mortality compared to usual care.
  • CT chest with IV contrast: Adding intravenous contrast increases radiation dose and introduces risks related to the contrast agent (e.g., allergic reaction, nephropathy) without improving the detection of early-stage lung cancer for screening purposes.
  • FDG-PET/CT: This is a high-radiation functional imaging study (adult RRL=☢☢☢☢ 10-30 mSv) used for staging known cancer or evaluating indeterminate nodules found on other imaging. It has no role as a primary screening tool due to its high cost, high radiation dose, and potential for false positives from inflammatory conditions.

What’s Next After Deciding Against Screening?

The clinical workflow does not end with the decision not to order imaging. The patient’s request for screening is an opportunity for proactive primary care and risk-reduction counseling, which is the most effective intervention for this population.

1. Counsel on Smoking Cessation: This is the single most important action. For the patient who still smokes, even lightly, provide resources and support for cessation. For the former smoker, reinforce the benefits of having quit and the continued reduction in risk over time. This has a far greater impact on their future health than any screening test.

2. Educate on the Rationale: Clearly explain why screening is not recommended for them. Frame the decision as one rooted in protecting them from the harms of unnecessary testing, such as false alarms, anxiety, and invasive procedures. Explain that the guidelines are based on extensive research to identify the specific group of people who benefit most.

3. Review and Mitigate Other Risk Factors: Discuss other potential risks, such as secondhand smoke exposure, occupational exposures (e.g., asbestos), and radon exposure in the home. Recommend radon testing if appropriate for their geographic location.

4. Emphasize Symptom Awareness: Instruct the patient to return for evaluation if they develop any new or concerning symptoms, such as a persistent cough, shortness of breath, chest pain, hoarseness, or unexplained weight loss. At that point, the clinical scenario shifts from asymptomatic screening to a diagnostic workup, where imaging would be appropriate.

Pitfalls to Avoid (and When to Get Help)

The primary pitfall in this scenario is ordering a screening study against guidelines due to patient pressure or a misinterpretation of screening criteria. This can initiate a cascade of low-yield, high-cost, and potentially harmful follow-up testing. Another common error is ordering a standard chest radiograph as a “compromise,” which provides false reassurance while lacking the sensitivity to be an effective screening tool. Finally, avoid dismissing the patient’s concerns; use their request as a teachable moment to discuss true risk reduction through lifestyle modification, particularly smoking cessation. If a patient’s risk profile is ambiguous or complex, a consultation with a pulmonologist can help clarify the appropriateness of screening.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to lung cancer screening, including workflows for high-risk patients, please see our parent topic hub article. The following GigHz tools can also assist in clinical decision-making for imaging.

Frequently Asked Questions

If a patient with a 15 pack-year history insists on a scan, what should I do?

The recommendation is to engage in shared decision-making, explaining clearly that for their level of risk, the potential harms from false positives, radiation, and follow-up procedures are believed to outweigh the benefits. The conversation should be documented, and the primary focus should be shifted to proven risk-reduction strategies, especially smoking cessation.

Does a family history of lung cancer change the recommendation for this patient?

A family history of lung cancer is a known risk factor. However, the specific scenario covered in this article assumes no additional risk factors. If a patient has a significant family history (e.g., a first-degree relative with lung cancer), they no longer fit this low-risk variant, and their case should be evaluated individually, potentially in consultation with a pulmonologist. Some guidelines consider this an indication for screening in patients with a lower pack-year history, but it falls outside this specific ACR workflow.

Why isn’t a chest X-ray a reasonable ‘light’ screening alternative?

Large clinical trials, such as the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, found that annual screening with chest radiography did not reduce lung cancer mortality compared to usual care. It has poor sensitivity for small, early-stage cancers and still produces false-positive findings, making it an ineffective screening tool.

At what point does a patient’s smoking history cross the threshold for screening?

According to current USPSTF and ACR guidelines, the threshold is a 20 pack-year smoking history. This is in combination with being between 50 and 80 years of age and either currently smoking or having quit within the last 15 years. A patient must meet all of these criteria to be considered eligible for routine annual screening with low-dose CT.

What if this patient develops a new cough? Does the ‘no screening’ rule still apply?

No. If the patient develops symptoms like a new, persistent cough, hemoptysis, or unexplained shortness of breath, the clinical context changes from asymptomatic screening to a diagnostic workup. In that case, imaging (typically starting with a chest radiograph, followed by CT if needed) is appropriate to evaluate the cause of the symptoms.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026